Almirall has announced today a strategic collaboration with Microsoft aimed at advancing digitalization and technological innovation in the field. The 3-year partnership seeks to advance medical dermatology research, develop next-generation personalized drugs, and accelerate Almirall's overall digital transformation. The primary focus of the collaboration is to leverage Almirall's extensive research and development expertise in dermatology drug discovery, combined with Microsoft's digital technologies, to expedite the development of innovative treatment options. The collaboration also aims to apply AI technologies to prioritize drug discovery based on novelty and commercialization potential before validation. This approach is expected to streamline the drug development process and enhance the efficiency of bringing novel treatments to market.